Sutro Biopharma (STRO) Receivables (2017 - 2026)
Sutro Biopharma (STRO) posted Receivables of $4.0 million for Q4 2025, up 1.4% sequentially from $3.9 million in Q3 2025, and down 53.84% YoY from $8.6 million in Q4 2024.
Sutro Biopharma (STRO) Receivables (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Receivables for 9 years, with the latest figure at $4.0 million in Q4 2025.
- Quarterly Receivables fell 53.84% year-over-year to $4.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.0 million (down 53.84% YoY) and the FY2025 annual result came in at $4.0 million, down 53.84% from the prior year.
- Receivables advanced to $4.0 million in Q4 2025 per STRO's latest filing, from $3.9 million in the prior quarter.
- Over five years, Receivables peaked at $97.7 million in Q2 2022 and troughed at $3.9 million in Q3 2025.
- A 5-year average of $16.2 million and a median of $9.9 million in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2023: Receivables soared 966.28% in 2022, then slumped 89.76% in 2023.
- Over 5 years, Receivables stood at $12.5 million in 2021, then slumped by 42.81% to $7.1 million in 2022, then surged by 406.57% to $36.1 million in 2023, then sank by 76.12% to $8.6 million in 2024, then plunged by 53.84% to $4.0 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $4.0 million, $3.9 million, and $8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | 5.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.80 Mn |
| Dec 31, 2025 | 3.98 Mn |
| Sep 30, 2025 | 3.92 Mn |
| Jun 30, 2025 | 8.00 Mn |
| Mar 31, 2025 | 13.56 Mn |
| Dec 31, 2024 | 8.62 Mn |
| Sep 30, 2024 | 6.66 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Mar 31, 2024 | 31.30 Mn |
| Dec 31, 2023 | 36.08 Mn |
| Sep 30, 2023 | 16.63 Mn |
| Jun 30, 2023 | 10.00 Mn |
| Mar 31, 2023 | 9.87 Mn |
| Dec 31, 2022 | 7.12 Mn |
| Sep 30, 2022 | 11.24 Mn |
| Jun 30, 2022 | 97.67 Mn |
| Mar 31, 2022 | 11.69 Mn |
| Dec 31, 2021 | 12.45 Mn |
| Sep 30, 2021 | 12.33 Mn |
| Jun 30, 2021 | 9.16 Mn |